These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 26086872)
1. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Chen Z; Wang W; Verstovsek S; Cortes JE; Medeiros LJ; Hu S Int J Lab Hematol; 2015 Dec; 37(6):e150-2. PubMed ID: 26086872 [No Abstract] [Full Text] [Related]
2. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib. Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144 [No Abstract] [Full Text] [Related]
3. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389 [No Abstract] [Full Text] [Related]
4. Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm. De Bruyne S; Steel E; Petrick M; Denys B; Vandepoele K; Van Roy N; Degandt S; Ghys T; Louagie H Clin Chem Lab Med; 2021 Sep; 59(10):e392-e394. PubMed ID: 33964201 [No Abstract] [Full Text] [Related]
6. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit? Gorbenko AS; Stolyar MA; Olkhovskiy IA; Vasiliev EV; Mikhalev MA Clin Chem Lab Med; 2019 Mar; 57(4):e60-e62. PubMed ID: 30157024 [No Abstract] [Full Text] [Related]
7. Molecular genetic evaluation of myeloproliferative neoplasms. Azzato EM; Bagg A Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962 [TBL] [Abstract][Full Text] [Related]
8. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders. Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037 [TBL] [Abstract][Full Text] [Related]
9. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356 [TBL] [Abstract][Full Text] [Related]
10. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL; J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506 [TBL] [Abstract][Full Text] [Related]
11. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476 [TBL] [Abstract][Full Text] [Related]
12. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature. Bader G; Dreiling B J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277 [TBL] [Abstract][Full Text] [Related]
13. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Shirane S; Araki M; Morishita S; Edahiro Y; Takei H; Yoo Y; Choi M; Sunami Y; Hironaka Y; Noguchi M; Koike M; Noda N; Ohsaka A; Komatsu N Haematologica; 2015 Feb; 100(2):e46-8. PubMed ID: 25398833 [No Abstract] [Full Text] [Related]
14. JAK2-V617F and BCR-ABL--double jeopardy? Krämer A Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674 [No Abstract] [Full Text] [Related]
15. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment. Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855 [No Abstract] [Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
19. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582 [TBL] [Abstract][Full Text] [Related]
20. Clinical acceleration of Ong J; Lin JI; Mitchell H; Morgan S; Perkins AC Haematologica; 2020 Aug; 105(8):e428-e431. PubMed ID: 32499240 [No Abstract] [Full Text] [Related] [Next] [New Search]